Abstract 12374: Visceral Fat Metabolic Activity is Independently Associated With Coronary Artery Inflammation in Patients With Impaired Glucose Intolerance or Type 2 Diabetes
OBJECTIVE: We have very recently demonstrated that pioglitazone could attenuate coronary artery inflammation evaluated by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) in patients with impaired glucose intolerance (IGT) or type 2 diabetes (T2DM) in a glucose-lowering independent manner. However, it remains unclear which clinical factors are associated with reduction of coronary artery inflammation.
METHODS: FDG-PET and CT were performed in 47 patients with IGT or T2DM (37 males and 10 females; mean age 68.1±8.3 years). These patients were randomized to treatment with either pioglitazone or glimepiride for 16 weeks. FDG uptakes in the left main trunk and visceral fat were normalized to background blood FDG activity as target-to-background ratio (TBR) to assess coronary artery inflammation (CAI) and visceral fat metabolic activity (VFA).
RESULTS: After 16-week treatments, fasting plasma glucose and HbA1c values were comparably reduced in both groups. TBR values in coronary artery and visceral fats were significantly decreased in pioglitazone-treated group, but not in glimepride-treated group. Changes in CAI from baseline (ΔCAI) were significantly correlated with Δuric acid (P=0.041) and ΔVFA (P=0.025). Multiple stepwise regression analysis revealed that ΔVFA was a sole independent correlate of ΔCAI (R2=0.109).
CONCLUSIONS: Our study suggests that VFA could play an important role in CAI and might be a marker to predict future cardiovascular events in patients with IGT or T2DM.
Author Disclosures: S. Igata: None. N. Tahara: None. A. Tahara: None. Y. Nitta: None. A. Honda: None. N. Kodama: None. M. Mizoguchi: None. S. Yamagishi: None. Y. Fukumoto: None.
- © 2014 by American Heart Association, Inc.